NO314628B1 - Nye N-arylpiperidin-forbindelser, en fremgangsmåte ved fremstilling derav og farmasöytiske preparater som inneholder slike - Google Patents

Nye N-arylpiperidin-forbindelser, en fremgangsmåte ved fremstilling derav og farmasöytiske preparater som inneholder slike Download PDF

Info

Publication number: NO314628B1
Authority: NO; Norway
Prior art keywords: dihydro; piperid; fumarate; amine; benzodioxin
Prior art date: 1997-03-27

Application number

NO19981415A

Other languages

English (en)

Norwegian (no)

Other versions

NO981415L (no

NO981415D0 (no

Inventor

Jean-Louis Peglion

Bertrand Goument

Mark Millan

Alain Gobert

Valerie Audinot

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-27

Filing date

1998-03-27

Publication date

2003-04-22

1998-03-27 Application filed by Servier Lab filed Critical Servier Lab

1998-03-27 Publication of NO981415D0 publication Critical patent/NO981415D0/no

1998-09-28 Publication of NO981415L publication Critical patent/NO981415L/no

2003-04-22 Publication of NO314628B1 publication Critical patent/NO314628B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 48
238000000034 method Methods 0.000 title claims description 9
238000002360 preparation method Methods 0.000 title description 25
239000000825 pharmaceutical preparation Substances 0.000 title description 4
230000008569 process Effects 0.000 title description 2
239000002253 acid Substances 0.000 claims abstract description 15
239000000203 mixture Substances 0.000 claims abstract description 11
150000003839 salts Chemical class 0.000 claims abstract description 6
230000003287 optical effect Effects 0.000 claims abstract description 5
125000000217 alkyl group Chemical group 0.000 claims abstract description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 43
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 41
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
238000011282 treatment Methods 0.000 claims description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 8
150000001412 amines Chemical class 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 5
125000004432 carbon atom Chemical group C* 0.000 claims description 4
230000002490 cerebral effect Effects 0.000 claims description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
206010019233 Headaches Diseases 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
208000019695 Migraine disease Diseases 0.000 claims description 3
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 3
238000007796 conventional method Methods 0.000 claims description 3
231100000869 headache Toxicity 0.000 claims description 3
QCMYGTCGYNYKRK-UHFFFAOYSA-N n-(7-bicyclo[4.2.0]octa-1(8),2,4,6-tetraenylmethyl)-1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound C1=CC=CC2=CC(CNC3CCN(CC3)C=3C=4OCCOC=4C=CC=3)=C21 QCMYGTCGYNYKRK-UHFFFAOYSA-N 0.000 claims description 3
AMKKLZCOUMIFKH-UHFFFAOYSA-N n-[2-(1-adamantyl)ethyl]-1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NCCC1(C2)CC(C3)CC2CC3C1 AMKKLZCOUMIFKH-UHFFFAOYSA-N 0.000 claims description 3
208000020016 psychiatric disease Diseases 0.000 claims description 3
208000011117 substance-related disease Diseases 0.000 claims description 3
230000002792 vascular Effects 0.000 claims description 3
MUBGRBXKGIFFDT-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-[(3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5,7-tetraenyl)methyl]piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NCC1=CC2=C1C=C(OC)C(OC)=C2 MUBGRBXKGIFFDT-UHFFFAOYSA-N 0.000 claims description 2
NBRVDCLEOKUTKR-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-[(8,9-dimethoxy-5,6-dihydropyrrolo[2,1-a]isoquinolin-2-yl)methyl]piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NCC1=CN2CCC(C=C(C(=C3)OC)OC)=C3C2=C1 NBRVDCLEOKUTKR-UHFFFAOYSA-N 0.000 claims description 2
ARAJVJPKMSFZBM-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-[3-(2,3-dihydro-1h-inden-1-yl)propyl]piperidin-4-amine Chemical compound C1CC2=CC=CC=C2C1CCCNC1CCN(C=2C=3OCCOC=3C=CC=2)CC1 ARAJVJPKMSFZBM-UHFFFAOYSA-N 0.000 claims description 2
PSUZUNWPCASNJA-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)-n-[2-(8,9-dimethoxy-5,6-dihydropyrrolo[2,1-a]isoquinolin-2-yl)ethyl]piperidin-4-amine Chemical compound C1CCOC2=C1C=CC=C2N(CC1)CCC1NCCC1=CN2CCC(C=C(C(=C3)OC)OC)=C3C2=C1 PSUZUNWPCASNJA-UHFFFAOYSA-N 0.000 claims description 2
208000032841 Bulimia Diseases 0.000 claims description 2
206010006550 Bulimia nervosa Diseases 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
208000002193 Pain Diseases 0.000 claims description 2
150000007513 acids Chemical class 0.000 claims description 2
208000022531 anorexia Diseases 0.000 claims description 2
206010061428 decreased appetite Diseases 0.000 claims description 2
206010013663 drug dependence Diseases 0.000 claims description 2
206010027599 migraine Diseases 0.000 claims description 2
NUQRZHZFQDBAFM-UHFFFAOYSA-N n-[2-(2-adamantyl)ethyl]-1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NCCC1C(C2)CC3CC2CC1C3 NUQRZHZFQDBAFM-UHFFFAOYSA-N 0.000 claims description 2
ZTOUONZZXDXFPR-UHFFFAOYSA-N n-[2-(2-adamantyl)ethyl]-1-(3,4-dihydro-2h-chromen-8-yl)piperidin-4-amine Chemical compound C1CCOC2=C1C=CC=C2N(CC1)CCC1NCCC1C(C2)CC3CC2CC1C3 ZTOUONZZXDXFPR-UHFFFAOYSA-N 0.000 claims description 2
MYFJUIKSBGNKNQ-UHFFFAOYSA-N n-[2-(7-bicyclo[4.2.0]octa-1(8),2,4,6-tetraenyl)ethyl]-1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NCCC1=C(C=CC=C2)C2=C1 MYFJUIKSBGNKNQ-UHFFFAOYSA-N 0.000 claims description 2
DZFRBYYLQGJHHX-UHFFFAOYSA-N n-[3-(7-bicyclo[4.2.0]octa-1,3,5,7-tetraenyl)propyl]-1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound C1=CC=C2C(CCCNC3CCN(CC3)C=3C=4OCCOC=4C=CC=3)=CC2=C1 DZFRBYYLQGJHHX-UHFFFAOYSA-N 0.000 claims description 2
SOCMZTXKKJHLSA-UHFFFAOYSA-N n-[4-(7-bicyclo[4.2.0]octa-1,3,5,7-tetraenyl)butyl]-1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NCCCCC1=CC2=CC=CC=C12 SOCMZTXKKJHLSA-UHFFFAOYSA-N 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
231100000241 scar Toxicity 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
QTWJBDZQVVGUPG-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-(2,3-dihydro-1h-inden-1-ylmethyl)piperidin-4-amine Chemical compound C1CC2=CC=CC=C2C1CNC1CCN(C=2C=3OCCOC=3C=CC=2)CC1 QTWJBDZQVVGUPG-UHFFFAOYSA-N 0.000 claims 1
QXHARRQXKGTENB-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-[2-(2,3-dihydro-1h-inden-1-yl)ethyl]piperidin-4-amine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCC1NCCC1C2=CC=CC=C2CC1 QXHARRQXKGTENB-UHFFFAOYSA-N 0.000 claims 1
239000004927 clay Substances 0.000 claims 1
NESXRYWWENJSPU-UHFFFAOYSA-N n-benzyl-1-(2,3-dihydro-1,4-benzodioxin-5-yl)-n-[2-(2,3-dihydro-1h-inden-1-yl)ethyl]piperidin-4-amine Chemical compound C1CC2=CC=CC=C2C1CCN(C1CCN(CC1)C=1C=2OCCOC=2C=CC=1)CC1=CC=CC=C1 NESXRYWWENJSPU-UHFFFAOYSA-N 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
239000000047 product Substances 0.000 description 56
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
RJVZEPWRJJBXLH-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-1-yl)acetic acid Chemical compound C1=CC=C2C(CC(=O)O)CCC2=C1 RJVZEPWRJJBXLH-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
239000000243 solution Substances 0.000 description 14
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
238000001704 evaporation Methods 0.000 description 10
230000008020 evaporation Effects 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
230000027455 binding Effects 0.000 description 8
229940076279 serotonin Drugs 0.000 description 8
102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 7
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
239000002585 base Substances 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
239000003446 ligand Substances 0.000 description 7
238000010992 reflux Methods 0.000 description 7
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000000556 agonist Substances 0.000 description 6
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
238000001035 drying Methods 0.000 description 6
238000001914 filtration Methods 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
235000019341 magnesium sulphate Nutrition 0.000 description 6
239000012071 phase Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
241000700198 Cavia Species 0.000 description 5
101150050738 HTR1B gene Proteins 0.000 description 5
241000700159 Rattus Species 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
239000003480 eluent Substances 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 4
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 4
101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
241000700199 Cavia porcellus Species 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000002295 serotoninergic effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000036506 anxiety Effects 0.000 description 3
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
229960003638 dopamine Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000012458 free base Substances 0.000 description 3
230000004807 localization Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229960002748 norepinephrine Drugs 0.000 description 3
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
VEBPRSTYWWNWEF-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=C1OCCO2 VEBPRSTYWWNWEF-UHFFFAOYSA-N 0.000 description 2
RWHQXNIVRDEPNN-UHFFFAOYSA-N 1-(6-fluoro-3,4-dihydro-2h-chromen-8-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC(F)=CC2=C1OCCC2 RWHQXNIVRDEPNN-UHFFFAOYSA-N 0.000 description 2
YOMZOXSDLMYPCV-UHFFFAOYSA-N 2-(5,6-dihydropyrrolo[2,1-a]isoquinolin-2-yl)acetic acid Chemical compound C12=CC=CC=C2CCN2C1=CC(CC(=O)O)=C2 YOMZOXSDLMYPCV-UHFFFAOYSA-N 0.000 description 2
AQMDWNQVYNHKMO-UHFFFAOYSA-N 2-(8,9-dimethoxy-5,6-dihydropyrrolo[2,1-a]isoquinolin-2-yl)acetic acid Chemical compound C1CN2C=C(CC(O)=O)C=C2C2=C1C=C(OC)C(OC)=C2 AQMDWNQVYNHKMO-UHFFFAOYSA-N 0.000 description 2
XNLXOWOPHABGRZ-UHFFFAOYSA-N 2-(8-chloro-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinolin-2-yl)acetic acid Chemical compound C12=CC(CC(O)=O)=CN2CCC2=C1C=C(OC)C(Cl)=C2 XNLXOWOPHABGRZ-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
-1 5,6-dihydro-8,9-dimethylpyrrolo[2,1-a]-isoquinol-2-carboxylic acid Chemical compound 0.000 description 2
101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 2
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000007527 Autoreceptors Human genes 0.000 description 2
108010071131 Autoreceptors Proteins 0.000 description 2
208000020401 Depressive disease Diseases 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
206010033664 Panic attack Diseases 0.000 description 2
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000036760 body temperature Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
231100000870 cognitive problem Toxicity 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000001530 fumaric acid Substances 0.000 description 2
230000002631 hypothermal effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
HFLMYYLFSNEOOT-UHFFFAOYSA-N methyl 4-chloro-3-oxobutanoate Chemical compound COC(=O)CC(=O)CCl HFLMYYLFSNEOOT-UHFFFAOYSA-N 0.000 description 2
238000001690 micro-dialysis Methods 0.000 description 2
208000019906 panic disease Diseases 0.000 description 2
229960001779 pargyline Drugs 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
WNUMFWKPEKSQJO-UHFFFAOYSA-N 1,5-dibromopentan-3-amine;hydrobromide Chemical compound Br.BrCCC(N)CCBr WNUMFWKPEKSQJO-UHFFFAOYSA-N 0.000 description 1
RBNZLNCNRVIFIJ-UHFFFAOYSA-N 1-(3,4-dihydro-2h-chromen-8-yl)piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=C1OCCC2 RBNZLNCNRVIFIJ-UHFFFAOYSA-N 0.000 description 1
DMLRSJNZORFCBD-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-5-amine Chemical compound O1CCOC2=C1C=CC=C2N DMLRSJNZORFCBD-UHFFFAOYSA-N 0.000 description 1
JBQMFBWTKWOSQX-UHFFFAOYSA-N 2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCC2=C1 JBQMFBWTKWOSQX-UHFFFAOYSA-N 0.000 description 1
SMDJRVLKRLINPR-UHFFFAOYSA-N 2-(7-bicyclo[4.2.0]octa-1(8),2,4,6-tetraenyl)acetic acid Chemical compound C1=CC=CC2=CC(CC(=O)O)=C21 SMDJRVLKRLINPR-UHFFFAOYSA-N 0.000 description 1
YBSGCPNACQAQDQ-UHFFFAOYSA-N 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5,7-tetraene-7-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC2=C1C(C(O)=O)=C2 YBSGCPNACQAQDQ-UHFFFAOYSA-N 0.000 description 1
UCKWJLDPHMBXEB-UHFFFAOYSA-N 3-(2,3-dihydro-1h-inden-1-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)CCC2=C1 UCKWJLDPHMBXEB-UHFFFAOYSA-N 0.000 description 1
ZNPMTYNUXRMTBE-UHFFFAOYSA-N 3-(7-bicyclo[4.2.0]octa-1(8),2,4,6-tetraenyl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CC2=C1 ZNPMTYNUXRMTBE-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
VDFXDCPJCORWLS-UHFFFAOYSA-N 4-(7-bicyclo[4.2.0]octa-1,3,5,7-tetraenyl)butanoic acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CC2=C1 VDFXDCPJCORWLS-UHFFFAOYSA-N 0.000 description 1
102000035038 5-HT1 receptors Human genes 0.000 description 1
108091005478 5-HT1 receptors Proteins 0.000 description 1
VASUQTGZAPZKFK-UHFFFAOYSA-N 6,7-Dimethoxy-1-methyl-3,4-dihydroisoquinoline Chemical compound C1CN=C(C)C2=C1C=C(OC)C(OC)=C2 VASUQTGZAPZKFK-UHFFFAOYSA-N 0.000 description 1
OKEJLLFDEURVDZ-UHFFFAOYSA-N 6-chloro-7-methoxy-1-methylisoquinoline Chemical compound N1=CC=C2C=C(Cl)C(OC)=CC2=C1C OKEJLLFDEURVDZ-UHFFFAOYSA-N 0.000 description 1
AEICTTXLAITIQJ-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromen-8-amine Chemical compound C1CCOC2=C1C=C(F)C=C2N AEICTTXLAITIQJ-UHFFFAOYSA-N 0.000 description 1
AADYIFLRRCYLRF-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromene Chemical compound O1CCCC2=CC(F)=CC=C21 AADYIFLRRCYLRF-UHFFFAOYSA-N 0.000 description 1
RSVLOWLCSDVHKN-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromene-8-carbaldehyde Chemical compound C1CCOC2=C1C=C(F)C=C2C=O RSVLOWLCSDVHKN-UHFFFAOYSA-N 0.000 description 1
DCDTYZGACGGIHH-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-chromene-8-carboxylic acid Chemical compound C1CCOC2=C1C=C(F)C=C2C(=O)O DCDTYZGACGGIHH-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
LLPLMVPHYZUQNW-UHFFFAOYSA-N 8,9-dimethoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-2-carboxylic acid Chemical compound C1CN2C=C(C(O)=O)C=C2C2=C1C=C(OC)C(OC)=C2 LLPLMVPHYZUQNW-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000017911 HTR1A Human genes 0.000 description 1
101150015707 HTR1A gene Proteins 0.000 description 1
239000003810 Jones reagent Substances 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
229910010066 TiC14 Inorganic materials 0.000 description 1
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
KYIJWVJKDWCRBL-UHFFFAOYSA-N benzyl n-(6-fluoro-3,4-dihydro-2h-chromen-8-yl)carbamate Chemical compound C=1C(F)=CC=2CCCOC=2C=1NC(=O)OCC1=CC=CC=C1 KYIJWVJKDWCRBL-UHFFFAOYSA-N 0.000 description 1
AASGLWBTIQEPOB-UHFFFAOYSA-N bicyclo[4.2.0]octa-1,3,5,7-tetraene-7-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC2=C1 AASGLWBTIQEPOB-UHFFFAOYSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000009529 body temperature measurement Methods 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
150000001844 chromium Chemical class 0.000 description 1
238000003869 coulometry Methods 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
BABIJAAOYPQRRO-UHFFFAOYSA-N ethyl 8,9-dimethoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2CCN2C1=CC(C(=O)OCC)=C2 BABIJAAOYPQRRO-UHFFFAOYSA-N 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
244000144980 herd Species 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000036651 mood Effects 0.000 description 1
COGGGWRHZQTITF-UHFFFAOYSA-N n-(oxan-4-ylidene)hydroxylamine Chemical compound ON=C1CCOCC1 COGGGWRHZQTITF-UHFFFAOYSA-N 0.000 description 1
XUBOFCIEDMCFES-UHFFFAOYSA-N n-[2-(8,9-dimethoxy-5,6-dihydropyrrolo[2,1-a]isoquinolin-2-yl)ethyl]-1-(6-fluoro-3,4-dihydro-2h-chromen-8-yl)piperidin-4-amine Chemical compound C1CCOC2=C1C=C(F)C=C2N(CC1)CCC1NCCC1=CN2CCC(C=C(C(=C3)OC)OC)=C3C2=C1 XUBOFCIEDMCFES-UHFFFAOYSA-N 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
KWZSCXIYGVEHOB-UHFFFAOYSA-N oxan-4-amine;hydrochloride Chemical compound [Cl-].[NH3+]C1CCOCC1 KWZSCXIYGVEHOB-UHFFFAOYSA-N 0.000 description 1
JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical group NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 1
LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
238000012552 review Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000020341 sensory perception of pain Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
238000012795 verification Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO19981415A 1997-03-27 1998-03-27 Nye N-arylpiperidin-forbindelser, en fremgangsmåte ved fremstilling derav og farmasöytiske preparater som inneholder slike NO314628B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9703760A FR2761358B1 (fr)	1997-03-27	1997-03-27	Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number	Publication Date
NO981415D0 NO981415D0 (no)	1998-03-27
NO981415L NO981415L (no)	1998-09-28
NO314628B1 true NO314628B1 (no)	2003-04-22

Family

ID=9505236

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19981415A NO314628B1 (no)	1997-03-27	1998-03-27	Nye N-arylpiperidin-forbindelser, en fremgangsmåte ved fremstilling derav og farmasöytiske preparater som inneholder slike

Country Status (17)

Country	Link
US (1)	US5965575A (2)
EP (1)	EP0867436B1 (2)
JP (1)	JPH10279578A (2)
CN (1)	CN1090628C (2)
AT (1)	ATE268767T1 (2)
AU (1)	AU731018B2 (2)
BR (1)	BR9803295A (2)
CA (1)	CA2232116C (2)
DE (1)	DE69824332T2 (2)
DK (1)	DK0867436T3 (2)
ES (1)	ES2223110T3 (2)
FR (1)	FR2761358B1 (2)
NO (1)	NO314628B1 (2)
NZ (1)	NZ330041A (2)
PL (1)	PL194118B1 (2)
PT (1)	PT867436E (2)
ZA (1)	ZA982607B (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2782515B1 (fr) *	1998-08-21	2000-09-22	Adir	NOUVEAUX DERIVES DE L'INDANE-1-Ol, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
JP2002535365A (ja) *	1999-01-28	2002-10-22	ブリストル−マイヤーズスクイブカンパニー	抗うつ性複素環化合物
EP1189900B1 (en) *	1999-06-30	2004-01-14	Bristol-Myers Squibb Company	Heterocyclic aminopyrrolidine derivatives as melatonergic agents
GB0013737D0 (en)	2000-06-07	2000-07-26	Astrazeneca Ab	Novel compounds
SE0103650D0 (sv) *	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic heterocyclic compounds
SE0103646D0 (sv) *	2001-11-01	2001-11-01	Astrazeneca Ab	Therapeutic chroman compounds
NZ526699A (en) *	2001-01-16	2005-03-24	Astrazeneca Ab	8-amino derivatives and their use in treating migraine
NZ535574A (en) *	2001-01-16	2006-07-28	Astrazeneca Ab	Therapeutic heterocyclic compounds
WO2002069973A1 (en) *	2001-03-02	2002-09-12	Sepracor, Inc.	Piperidine-piperazine ligand for neurotransmitter receptors
SE0103836D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Novel compounds
JP2005343790A (ja) *	2002-05-31	2005-12-15	Ajinomoto Co Inc	カルシウムチャネル拮抗薬を含有する医薬組成物
SE0300480D0 (sv)	2003-02-21	2003-02-21	Astrazeneca Ab	Novel compounds
GB0312609D0 (en)	2003-06-02	2003-07-09	Astrazeneca Ab	Novel compounds
ES2331519T3 (es) *	2003-06-30	2010-01-07	Nycomed Gmbh	Derivados de pirrolo-dihidroisoquinolina como inhibidores de pde10.
RS20050945A (sr) *	2003-06-30	2008-06-05	Altana Pharma Ag.,	Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera
EP1661894A4 (en) *	2003-07-14	2007-02-28	Ube Industries	METHOD FOR PRODUCING 4-AMINOTETRAHYDROPYRANES AND THEIR SALTS WITH ACIDS, INTERMEDIATE PRODUCTS FOR THE METHOD AND METHOD FOR THE PRODUCTION THEREOF
AR045258A1 (es) *	2003-08-21	2005-10-19	Altana Pharma Ag	Un producto farmaceutico para inyeccion
US20060085924A1 (en) *	2004-10-13	2006-04-27	Gaelle Brun	Coloring composition comprising at least one pigment and at least one electrophilic cyanoacrylate monomer
AU2006218054A1 (en) *	2005-01-12	2006-08-31	Nycomed Gmbh	Novel pyrrolodihydroisoquinolines as PDE10 inhibitors
WO2006075012A2 (en) *	2005-01-12	2006-07-20	Nycomed Gmbh	Pyrrolodihydroisoquinolines as antiproliferative agents
US8599822B2 (en) *	2005-03-23	2013-12-03	Cisco Technology, Inc.	Slot-based transmission synchronization mechanism in wireless mesh networks
FR2884251B1 (fr) *	2005-04-08	2007-07-13	Servier Lab	Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY29892A1 (es) *	2005-11-04	2007-06-29	Astrazeneca Ab	Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
MX2008014450A (es)	2006-05-18	2009-03-09	Mannkind Corp	Inhibidores de cinasa intracelular.
BRPI0809106A2 (pt)	2007-03-22	2014-08-26	Astrazeneca Ab	Derivados de quinolina para o tratamento de doenças inflamatórias
US8106073B2 (en)	2007-11-30	2012-01-31	Astrazeneca Ab	Quinoline derivatives 057
TW200944523A (en) *	2008-02-08	2009-11-01	Organon Nv	(Dihydro)pyrrolo[2,1-a]isoquinolines
WO2020183011A1 (en)	2019-03-14	2020-09-17	Institut Curie	Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2692264B1 (fr) *	1992-06-12	1994-08-05	Adir	Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
GB9318431D0 (en) *	1993-09-06	1993-10-20	Boots Co Plc	Therapeutic agents
FR2734819B1 (fr) *	1995-05-31	1997-07-04	Adir	Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant

1997
- 1997-03-27 FR FR9703760A patent/FR2761358B1/fr not_active Expired - Fee Related
1998
- 1998-03-12 CA CA002232116A patent/CA2232116C/fr not_active Expired - Fee Related
- 1998-03-26 NZ NZ330041A patent/NZ330041A/xx unknown
- 1998-03-26 EP EP98400711A patent/EP0867436B1/fr not_active Expired - Lifetime
- 1998-03-26 PT PT98400711T patent/PT867436E/pt unknown
- 1998-03-26 CN CN98109437A patent/CN1090628C/zh not_active Expired - Fee Related
- 1998-03-26 AT AT98400711T patent/ATE268767T1/de not_active IP Right Cessation
- 1998-03-26 DE DE69824332T patent/DE69824332T2/de not_active Expired - Fee Related
- 1998-03-26 PL PL325575A patent/PL194118B1/pl not_active IP Right Cessation
- 1998-03-26 ES ES98400711T patent/ES2223110T3/es not_active Expired - Lifetime
- 1998-03-26 DK DK98400711T patent/DK0867436T3/da active
- 1998-03-27 BR BR9803295A patent/BR9803295A/pt not_active Application Discontinuation
- 1998-03-27 US US09/049,233 patent/US5965575A/en not_active Expired - Fee Related
- 1998-03-27 ZA ZA982607A patent/ZA982607B/xx unknown
- 1998-03-27 NO NO19981415A patent/NO314628B1/no unknown
- 1998-03-27 AU AU59677/98A patent/AU731018B2/en not_active Ceased
- 1998-03-27 JP JP10081710A patent/JPH10279578A/ja active Pending

Also Published As

Publication number	Publication date
ATE268767T1 (de)	2004-06-15
BR9803295A (pt)	2000-03-21
EP0867436A1 (fr)	1998-09-30
EP0867436B1 (fr)	2004-06-09
FR2761358A1 (fr)	1998-10-02
DE69824332D1 (de)	2004-07-15
FR2761358B1 (fr)	1999-05-07
ES2223110T3 (es)	2005-02-16
PL325575A1 (en)	1998-09-28
CA2232116C (fr)	2003-09-16
CN1197072A (zh)	1998-10-28
DE69824332T2 (de)	2005-06-16
PL194118B1 (pl)	2007-04-30
JPH10279578A (ja)	1998-10-20
AU731018B2 (en)	2001-03-22
DK0867436T3 (da)	2004-10-04
HK1014954A1 (en)	1999-10-08
US5965575A (en)	1999-10-12
CA2232116A1 (fr)	1998-09-27
NO981415L (no)	1998-09-28
PT867436E (pt)	2004-09-30
AU5967798A (en)	1998-10-01
CN1090628C (zh)	2002-09-11
NO981415D0 (no)	1998-03-27
ZA982607B (en)	1998-09-30
NZ330041A (en)	1999-01-28

Publication	Publication Date	Title
NO314628B1 (no)	2003-04-22	Nye N-arylpiperidin-forbindelser, en fremgangsmåte ved fremstilling derav og farmasöytiske preparater som inneholder slike
JP4150161B2 (ja)	2008-09-17	置換されたクロマン誘導体
CA2839438C (en)	2020-08-04	Agents and methods for treating ischemic and other diseases
AU2010323175A1 (en)	2012-05-10	Morpholinothiazoles as alpha 7 positive allosteric modulators
JP2017503837A (ja)	2017-02-02	ピリジン類及びピリミジン類並びにその使用
JP2010528037A (ja)	2010-08-19	５−ｈｔ６受容体親和性を有する４’置換化合物
JP5455130B2 (ja)	2014-03-26	複素環式誘導体
CA2316388C (en)	2009-09-08	Tetrahydrobenzindole derivative
Matera et al.	2019	The novel hybrid agonist HyNDA-1 targets the D3R-nAChR heteromeric complex in dopaminergic neurons
JP6267334B2 (ja)	2018-01-24	５−ｈｔ６拮抗薬としてのピロロキノリン誘導体、それらの製造方法および使用
TWI421079B (zh)	2014-01-01	二苯并〔ｂ，ｆ〕〔１，４〕氧氮呯化合物
TW202031645A (zh)	2020-09-01	作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
JP2010517926A (ja)	2010-05-27	グルタミン酸受容体を増強する、統合失調症の治療に有用な４−フェニル−３−（２−プロピルスルホニルアミノ）テトラヒドロフラン誘導体
US5968954A (en)	1999-10-19	2-aminoindan compounds as 5HT1B antagonists
US6153625A (en)	2000-11-28	Indan-1-ol compounds
KR101279689B1 (ko)	2013-06-27	4-아미노-5-시아노피리미딘 유도체
NO316693B1 (no)	2004-03-26	Nye indanolforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem
JP2008509961A (ja)	2008-04-03	５−ｈｔ７受容体アンタゴニスト
WO2024026568A1 (en)	2024-02-08	Fused heterocyclic mescaline derivatives
CZ20012643A3 (cs)	2002-01-16	Nové morfolinobenzamidové soli
PL211061B1 (pl)	2012-04-30	Pochodne oksazolu, sposób ich wytwarzania, ich zastosowanie i kompozycja farmaceutyczna
JP2010517927A (ja)	2010-05-27	グルタミン酸受容体を増強する化合物および医学におけるその使用
JP2025540259A (ja)	2025-12-11	新規置換ピラジン－カルボキサミド－イミダゾピリジン誘導体
Rodenhuis	2000	New, centrally acting dopaminergic agents with an improved oral bioavailability: synthesis and pharmacological evaluation
JP2007056005A (ja)	2007-03-08	新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途